Hemogenyx Pharmplc Ls 01 Stock Shares Owned By Insiders
| 5HU Stock | EUR 3.79 0.01 0.26% |
HEMOGENYX PHARMPLC LS 01 fundamentals help investors to digest information that contributes to HEMOGENYX PHARMPLC's financial success or failures. It also enables traders to predict the movement of HEMOGENYX Stock. The fundamental analysis module provides a way to measure HEMOGENYX PHARMPLC's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to HEMOGENYX PHARMPLC stock.
HEMOGENYX |
HEMOGENYX PHARMPLC LS 01 Company Shares Owned By Insiders Analysis
HEMOGENYX PHARMPLC's Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current HEMOGENYX PHARMPLC Shares Owned By Insiders | 15.17 % |
Most of HEMOGENYX PHARMPLC's fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, HEMOGENYX PHARMPLC LS 01 is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
| Competition |
Based on the latest financial disclosure, 15.172% of HEMOGENYX PHARMPLC LS 01 are shares owned by insiders. This indicator is about the same for the Healthcare average (which is currently at 15.18) sector and 7.0% higher than that of the Biotechnology industry. The shares owned by insiders for all Germany stocks is 50.37% lower than that of the firm.
HEMOGENYX Shares Owned By Insiders Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses HEMOGENYX PHARMPLC's direct or indirect competition against its Shares Owned By Insiders to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of HEMOGENYX PHARMPLC could also be used in its relative valuation, which is a method of valuing HEMOGENYX PHARMPLC by comparing valuation metrics of similar companies.HEMOGENYX PHARMPLC is currently under evaluation in shares owned by insiders category among its peers.
HEMOGENYX Fundamentals
| Return On Equity | -0.32 | |||
| Return On Asset | -0.18 | |||
| Shares Outstanding | 979.75 M | |||
| Shares Owned By Insiders | 15.17 % | |||
| EBITDA | (2.62 M) | |||
| Net Income | (2.08 M) | |||
| Cash And Equivalents | 1.81 M | |||
| Total Debt | 1.63 M | |||
| Debt To Equity | 1.86 % | |||
| Current Ratio | 1.08 X | |||
| Book Value Per Share | 0.01 X | |||
| Cash Flow From Operations | (1.8 M) | |||
| Earnings Per Share | (0.01) X | |||
| Number Of Employees | 10 | |||
| Beta | 3.34 | |||
| Market Capitalization | 24.89 M | |||
| Z Score | 9.0 |
About HEMOGENYX PHARMPLC Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze HEMOGENYX PHARMPLC LS 01's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of HEMOGENYX PHARMPLC using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of HEMOGENYX PHARMPLC LS 01 based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in HEMOGENYX Stock
HEMOGENYX PHARMPLC financial ratios help investors to determine whether HEMOGENYX Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in HEMOGENYX with respect to the benefits of owning HEMOGENYX PHARMPLC security.